Characterisation of palliative sedation use in inpatients at a medium-stay palliative care unit
| Autor: | Nallely A. García-López, José Guzmán-Esquivel, Efrén Murillo-Zamora, Ana de Santiago-Ruiz, Alcira Emperatriz Chávez-Lira, Oliver Mendoza-Cano |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Advanced and Specialized Nursing
medicine.medical_specialty Inpatients Palliative care medicine.drug_class business.industry Midazolam Palliative Care Palliative sedation 03 medical and health sciences 0302 clinical medicine Cross-Sectional Studies 030220 oncology & carcinogenesis Sedative Hospice and Palliative Care Nursing medicine Humans Hypnotics and Sedatives Symptom control 030212 general & internal medicine Intensive care medicine business medicine.drug |
| Zdroj: | International journal of palliative nursing. 26(7) |
| ISSN: | 2052-286X |
| Popis: | Background Palliative sedation has been used to refer to the practice of providing symptom control through the administration of sedative drugs. The objective of this article was to characterise palliative sedation use in inpatients at a medium-stay palliative care unit. Material and methods A cross-sectional study was conducted on 125 randomly selected patients (aged 15 or older) who had died in 2014. The Palliative Performance Scale was used to evaluate the functional status. Results Palliative sedation was documented in 34.4% of the patients and midazolam was the most commonly used sedative agent (86.0%). More than half (53.5%) of those who recieved sedation presented with delirium. Liver dysfunction was more frequent in the sedated patients (p=0.033) and patients with heart disease were less likely (p=0.026) to be sedated. Conclusion Palliative sedation is an ethically accepted practice. It was commonly midazolam-induced, and differences were documented, among sedated and non-sedated patients, in terms of liver dysfunction and heart disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|